S&P 500

5.487,22

0,17%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
NanoViricides Inc (NNVC)
NanoViricides Inc (NNVC) Notícias

NNVC

NanoViricides (NNVC)

NanoViricides Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:AMEX:NNVC

1 2 3 4 5 6 7 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
02/05/2024	11:07	InvestorsHub NewsWire	NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon	AMEX:NNVC	NanoViricides Inc
16/02/2024	18:53	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:NNVC	NanoViricides Inc
14/02/2024	18:55	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:NNVC	NanoViricides Inc
04/12/2023	18:08	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	AMEX:NNVC	NanoViricides Inc
13/10/2023	17:30	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	AMEX:NNVC	NanoViricides Inc
28/09/2023	17:44	Edgar (US Regulatory)	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405	AMEX:NNVC	NanoViricides Inc
06/07/2023	12:16	InvestorsHub NewsWire	Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs	AMEX:NNVC	NanoViricides Inc
25/05/2023	17:34	Edgar (US Regulatory)	Current Report Filing (8-k)	AMEX:NNVC	NanoViricides Inc
08/05/2023	18:20	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3/a)	AMEX:NNVC	NanoViricides Inc
04/05/2023	07:45	GlobeNewswire Inc.	NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City	AMEX:NNVC	NanoViricides Inc
14/02/2023	19:24	Edgar (US Regulatory)	Quarterly Report (10-q)	AMEX:NNVC	NanoViricides Inc
23/12/2022	08:04	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	AMEX:NNVC	NanoViricides Inc
15/11/2022	18:32	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	AMEX:NNVC	NanoViricides Inc
04/11/2022	17:33	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	AMEX:NNVC	NanoViricides Inc
13/10/2022	18:13	Edgar (US Regulatory)	Annual Report (10-k)	AMEX:NNVC	NanoViricides Inc
29/09/2022	13:20	Edgar (US Regulatory)	Notification That Annual Report Will Be Submitted Late (nt 10-k)	AMEX:NNVC	NanoViricides Inc
10/08/2022	19:52	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	AMEX:NNVC	NanoViricides Inc
15/11/2021	09:09	InvestorsHub NewsWire	NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2	AMEX:NNVC	NanoViricides Inc
11/10/2021	07:49	InvestorsHub NewsWire	NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity	AMEX:NNVC	NanoViricides Inc
05/10/2021	07:45	PR Newswire (US)	NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference	AMEX:NNVC	NanoViricides Inc
22/09/2021	07:48	InvestorsHub NewsWire	Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug	AMEX:NNVC	NanoViricides Inc
14/09/2021	08:02	InvestorsHub NewsWire	NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development	AMEX:NNVC	NanoViricides Inc
09/03/2021	11:30	InvestorsHub NewsWire	NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont	AMEX:NNVC	NanoViricides Inc
02/03/2021	09:00	InvestorsHub NewsWire	NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical	AMEX:NNVC	NanoViricides Inc
17/02/2021	09:00	InvestorsHub NewsWire	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont	AMEX:NNVC	NanoViricides Inc
16/02/2021	11:48	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	AMEX:NNVC	NanoViricides Inc
08/02/2021	08:36	InvestorsHub NewsWire	NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C...	AMEX:NNVC	NanoViricides Inc
27/01/2021	09:00	InvestorsHub NewsWire	Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants	AMEX:NNVC	NanoViricides Inc
03/12/2020	18:31	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	AMEX:NNVC	NanoViricides Inc
19/11/2020	08:47	InvestorsHub NewsWire	NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA	AMEX:NNVC	NanoViricides Inc